CML Treatment Updates

Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.